Abstract: A method for producing a ? light chain antibody having enzyme activity or improved enzyme activity includes modifying a polynucleotide that encodes a ? light chain antibody having a polypeptide having an amino acid sequence where the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is a proline residue, to delete or substitute the proline residue and to obtain a polynucleotide that encodes a ? light chain antibody having a polypeptide having an amino acid sequence where the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue, and expressing a ? light chain antibody having enzyme activity in an intracellular or extracellular expression system by using an expression vector including the polynucleotide that encodes a ? light chain antibody obtained after modification.

Abstract: A human antibody ? type light chain complex-containing composition includes a complex in which a human antibody ? type light chain is bound to one or more kinds of metal ions selected from the group consisting of Group 10 elements, Group 11 elements, and Group 12 elements. The human antibody ? type light chain is a dimer, cysteines at C terminals of two human antibody ? type light chains are bound to each other via the metal ion, and 0.1 mol or more of the metal ion is bound per 1 mol of the human antibody ? type light chain.

Abstract: A human antibody ? type light chain complex-containing composition includes a complex in which a human antibody ? type light chain is bound to one or more kinds of metal ions selected from the group consisting of Group 10 elements, Group 11 elements, and Group 12 elements. The human antibody ? type light chain is a dimer, cysteines at C terminals of two human antibody ? type light chains are bound to each other via the metal ion, and 0.1 mol or more of the metal ion is bound per 1 mol of the human antibody ? type light chain.

Abstract: According to the present invention, an anticancer agent is provided that has as an active ingredient thereof a human antibody light chain that demonstrates cytotoxicity against cancer cells and particularly lung cancer cells. The anticancer agent of the present invention primarily comprises: a human antibody ?-type light chain in the form of a dimer in which the variable region is composed of a polypeptide represented by the amino acid sequence of SEQ ID NO: 1, 9 or 13 or an amino acid sequence in which one or a plurality of amino acids have been added, deleted or substituted in these amino acid sequences; or, a human antibody ?-type light chain in the form of a monomer in which the variable region is composed of a polypeptide represented by the amino acid sequence of SEQ ID NO: 19 or an amino acid sequence in which one or a plurality of amino acids have been added, deleted or substituted in the amino acid sequence.

Abstract: According to the present invention, an anticancer agent is provided that has as an active ingredient thereof a human antibody light chain that demonstrates cytotoxicity against cancer cells and particularly lung cancer cells. The anticancer agent of the present invention primarily comprises: a human antibody ?-type light chain in the form of a dimer in which the variable region is composed of a polypeptide represented by the amino acid sequence of SEQ ID NO: 1, 9 or 13 or an amino acid sequence in which one or a plurality of amino acids have been added, deleted or substituted in these amino acid sequences; or, a human antibody ?-type light chain in the form of a monomer in which the variable region is composed of a polypeptide represented by the amino acid sequence of SEQ ID NO: 19 or an amino acid sequence in which one or a plurality of amino acids have been added, deleted or substituted in the amino acid sequence.

Abstract: The present invention provides: a novel antiviral agent containing a human antibody ? light chain, a novel human abzyme containing a human antibody ? light chain; a polynucleotide, a vector, and a transformant, encoding a human antibody ? light chain of the above; a primer set for effectively obtaining a human antibody ? light chain having a function as an antiviral agent or abzyme; and a method for producing a polynucleotide and a method for producing a polypeptide, each of which method utilizes the primer set.

Abstract: According to the present invention, an anticancer agent is provided that has as an active ingredient thereof a human antibody light chain that demonstrates cytotoxicity against cancer cells and particularly lung cancer cells. The anticancer agent of the present invention primarily comprises: a human antibody ?-type light chain in the form of a dimer in which the variable region is composed of a polypeptide represented by the amino acid sequence of SEQ ID NO: 1, 9 or 13 or an amino acid sequence in which one or a plurality of amino acids have been added, deleted or substituted in these amino acid sequences; or, a human antibody ?-type light chain in the form of a monomer in which the variable region is composed of a polypeptide represented by the amino acid sequence of SEQ ID NO: 19 or an amino acid sequence in which one or a plurality of amino acids have been added, deleted or substituted in the amino acid sequence.

Abstract: The present invention provides: a novel antiviral agent containing a human antibody ? light chain, a novel human abzyme containing a human antibody ? light chain; a polynucleotide, a vector, and a transformant, each of which relating to the containing a human antibody ? light chain of the above; a primer set for effectively obtaining a human antibody ? light chain having a function as an antiviral agent or abzyme; and a method for producing a polynucleotide and a method for producing a polypeptide, each of which method utilizes the primer set.

Abstract: An apparatus for measuring a medical substance where a prism having a high refractive index, a thin metal film formed on one of the surfaces of the prism, a light source for making a light incident upon the thin metal film, and a detector for detecting an incident angle of a light being made incident upon a film on which a plasmon resonance phenomenon is generated on the thin metal film are provided. The medical substance, i.e. antigen as an object to be measured, is fixed to the surface of the thin metal film, and the condition for generating the plasmon resonance phenomenon is varied when a mixture of antibody which is coupled with the medical substance in a specific manner and a sample is made contact with a surface of the thin metal film; and the amount of the medical substance can be detected by recognizing the change with a high sensitivity.

Abstract: A process for producing an antibody enzyme which involves an antibody structure analysis step of confirming the presence of a catalyst triplet residue structure wherein a serine residue, an aspartate residue and a histidine residue or a glutamate residue are located stereostructurally close to each other in the stereostructure of an antibldy anticipated based on its amino acid sequence. Since the above-described catalyst triplet residue structure is a structure specific to an antibody enzyme, an antibody enzyme can be efficiently screened by using the same. Examples of the antibody enzyme as described above include an antibody enzyme against Helicobacter pylori urease and an antibody enzyme against chemokine receptor CCR-5.

Abstract: An apparatus for measuring a medical substance where a prism having a high refractive index, a thin metal film formed on one of the surfaces of the prism, a light source for making a light incident upon the thin metal film, and a detector for detecting an incident angle of a light being made incident upon a film on which a plasmon resonance phenomenon is generated on the thin metal film are provided. The medical substance, i.e. antigen as an object to be measured, is fixed to the surface of the thin metal film, and the condition for generating the plasmon resonance phenomenon is varied when a mixture of antibody which is coupled with the medical substance in a specific manner and a sample is made contact with a surface of the thin metal film; and the amount of the medical substance can be detected by recognizing the change with a high sensitivity.

Abstract: A monoclonal antibody which specifically binds okadaic acids and a process for producing the monoclonal antibody by culturing a cell strain capable of producing the antibody. The monoclonal antibody to okadaic acids labelled with an enzyme is useful for assaying okadaic acids.

Abstract: A monoclonal antibody against human manganese-superoxide dismutase characterized in that it is produced by a cell line which has been obtained by immunization of a mouse with human Mn-SOD and then fusion of lymphocytes obtained from the mouse with mouse myeloma cells, and has high specificity against human Mn-SOD; a method for producing a monoclonal antibody against human Mn-SOD having high specificity against human Mn-SOD, which comprises culturing the cell line obtained by immunization of a mouse with human Mn-SOD and then cell fusion of lymphocytes obtained from the mouse with mouse myeloma cells; a kit for assaying human Mn-SOD, comprising:(a) a monoclonal antibody having very high specific immuno-reactivity against human Mn-SOD; and(b) a reagent of a monoclonal antibody having very high specific immuno-reactivity against human Mn-SOD labelled with an enzyme (enzyme labelled antibody); a method for assaying human Mn-SOD use of the kit; a novel diagnostic method of human epithelial ovarian cancer, which co

Abstract: Monomeric synthetic peptide and dimeric synthetic peptide comprising an amino acid sequence represented by the formula:X-Asn-Val-Thr-Glu-Arg-Tyr-Met-Ala-Cys-Lys-LyswhereinX represents a residue comprising 0 to 10 amino acids sequence; and Asn represents aspartic acid, Val valine, Thr threonine, Glu glutamic acid, Arg arginine, Tyr tyrosine, Met methionine, Ala alanine, Cys cysteine and Lys lysine;an assay kit of human Mn-SOD to be used in the assay method of human Mn (manganese)-SOD comprising as essential components:(a) at least one of the above monomeric and dimeric synthetic peptides; and(b) an enzyme-labelled monoclonal antibody having a very high specific immunoreactivity against at least one of the above monomeric and dimeric synthetic peptides and at the same time having a very high specific immunoreactivity against human Mn-SOD; and an assay method of human Mn-SOD, which comprises immobilizing at least one of the above monomeric and dimeric synthetic peptides on a carrier, then allowing human Mn-SOD i

Abstract: There is disclosed a measurement reagent for a human Cu.Zn-superoxide dismutase (SOD) which comprises an anti-human Cu.Zn-SOD monoclonal antibody labelled with an enzyme, a method for measuring a human Cu.Zn-SOD which comprises measuring the human Cu.Zn-SOD with the measurement reagent for the human Cu.Zn-SOD, and an anti-human Cu.Zn-SOD monoclonal antibody by the enzyme-linked immunosorbent assay according to the sandwich method, a diagnostic test drug for a human cancer of the stomach which comprises the measurement reagent and a method for diagnosing and testing a human cancer of the stomach which comprises measuring the human Cu.Zn-superoxide dismutase with the measurement reagent, and an anti-human Cu.Zn-superoxide dismutase monoclonal antibody by the enzyme-linked immunosorbent assay according to the sandwich method.

Abstract: A hydrogenation catalyst composition useful for the hydrogenation of an oxalate diester, said composition being composed of a reduction product of a copper-containing silica gel formed by contacting an amine complex of copper with silica gel having an average particle diameter of not more than 200.mu. and a process for producing the aforesaid composition. Using a catalyst composed of the aforesaid composition, ethylene glycol and/or a glycolic acid ester can be produced from an oxalate diester efficiently with high conversions and selectivities and without causing pollution attributed to the use of a chromium-containing catalyst composition.

Abstract: A hydrogenation catalyst composition composed of a reduction product of a copper-containing material formed by contacting an aqueous solution of an amine/copper complex with a carrier, characterized in that the carrier is a hydrolyzed product obtained by hydrolyzing a silicate ester in the presence of ammonia; a process for producing the aforesaid hydrogenation catalyst composition; and a process for producing ethylene glycol or a glycolate ester in the presence of the aforesaid hydrogenation catalyst.

Abstract: A hydrogenation catalyst composition useful for the hydrogenation of an oxalate diester, said composition being composed of a reduction product of copper-containing silica gel formed by contacting an ammine complex of copper with colloidal silica sol; and a process for producing the aforesaid composition. Using a catalyst composed of the aforesaid composition, ethylene glycol and/or a glycolic acid ester can be produced from an oxalate diester efficiently with high conversions and selectivities and without causing pollution attributed to the use of a chromium-containing catalyst composition.

Abstract: In a process for producing ethylene glycol and/or a glycollic acid ester by the vapor phase catalytic hydrogenation of an oxalic acid diester in the presence of a catalyst and hydrogen gas, the improvement wherein the catalyst has the following composition formulaCuMo.sub.k Ba.sub.p O.sub.qwherein k, p and q represent gram-atoms of Mo, Ba and O, respectively, per gram-atom of Cu, k is a number of from 0 to 3, p is a number of from 0 to 6, and q is a number determined depending upon the atomic valence and gram-atoms of Cu, Mo and Ba, provided that k and p are not zero at the same time; and the aforesaid catalyst.

Abstract: A hydrogenation catalyst composition for use in the hydrogenation of a lower alkyl ester of a lower hydroxycarboxylic acid. The composition is composed of a reduction product of copper-containing silica gel formed by contacting an ammine complex of copper with silica gel having an average particle diameter of not more than 200 microns or colloidal silica sol. A process for producing the catalyst composition is also provided. By using the aforesaid catalyst composition, a lower alkylene glycol can be produced efficiently in high conversions and selectivities without causing pollution attributed to the use of a chromium-containing catalyst composition.